What is HC Wainwright’s Forecast for PCRX Q1 Earnings?

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Pacira BioSciences in a research report issued on Monday, March 30th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of $0.21 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.41 per share. HC Wainwright also issued estimates for Pacira BioSciences’ Q2 2027 earnings at $0.37 EPS, Q3 2027 earnings at $0.41 EPS, Q4 2027 earnings at $0.49 EPS and FY2027 earnings at $1.49 EPS.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing the consensus estimate of $0.85 by ($0.28). The company had revenue of $196.87 million for the quarter, compared to the consensus estimate of $201.93 million. Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.91 EPS.

Several other research analysts have also commented on the company. Wall Street Zen lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Zacks Research lowered Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research report on Monday, March 9th. Barclays reduced their price objective on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, December 29th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Pacira BioSciences in a research note on Friday, January 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $30.25.

Pacira BioSciences Stock Down 0.4%

Shares of Pacira BioSciences stock opened at $22.70 on Wednesday. The business has a 50-day moving average price of $22.11 and a 200 day moving average price of $23.29. Pacira BioSciences has a fifty-two week low of $18.80 and a fifty-two week high of $27.64. The firm has a market cap of $919.12 million, a P/E ratio of 151.33 and a beta of 0.19. The company has a quick ratio of 3.28, a current ratio of 4.54 and a debt-to-equity ratio of 0.54.

Insider Buying and Selling

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,261 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the completion of the transaction, the insider owned 223,640 shares in the company, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Lauren Riker sold 4,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $20.81, for a total value of $83,240.00. Following the completion of the transaction, the senior vice president directly owned 52,313 shares of the company’s stock, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 8,677 shares of company stock valued at $191,980 over the last three months. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

Several institutional investors have recently bought and sold shares of the stock. Hantz Financial Services Inc. grew its position in Pacira BioSciences by 175.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock valued at $29,000 after buying an additional 721 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Pacira BioSciences by 5,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock worth $39,000 after buying an additional 1,475 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Pacira BioSciences during the 4th quarter worth about $48,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Pacira BioSciences in the 4th quarter worth approximately $51,000. Finally, Global Retirement Partners LLC lifted its stake in shares of Pacira BioSciences by 479.4% in the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock worth $52,000 after acquiring an additional 1,678 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.